ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma.
Adolescent
Animals
Cell Line, Tumor
Cytokine-Induced Killer Cells
/ immunology
Humans
Immunity, Innate
/ immunology
Immunotherapy, Adoptive
/ methods
Killer Cells, Natural
/ immunology
Male
Mice
Mice, Inbred NOD
Mice, SCID
Natural Killer T-Cells
/ immunology
Receptor, ErbB-2
/ immunology
Receptors, Antigen, T-Cell
/ immunology
Receptors, Chimeric Antigen
/ immunology
Rhabdomyosarcoma
/ immunology
Xenograft Model Antitumor Assays
ERBB2 (HER2/neu)
cellular therapy
chimeric antigen receptor
cytokine-induced killer cells
rhabdomyosarcoma
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
08
07
2020
accepted:
07
09
2020
entrez:
16
11
2020
pubmed:
17
11
2020
medline:
23
6
2021
Statut:
epublish
Résumé
High-risk rhabdomyosarcoma (RMS) occurring in childhood to young adulthood is associated with a poor prognosis; especially children above the age of 10 with advanced stage alveolar RMS still succumb to the disease within a median of 2 years. The advent of chimeric antigen receptor (CAR)-engineered T cells marked significant progress in the treatment of refractory B cell malignancies, but experience for solid tumors has proven challenging. We speculate that this is at least in part due to the poor quality of the patient's own T cells and therefore propose using CAR-modified cytokine-induced killer (CIK) cells as effector cells. CIK cells are a heterogeneous population of polyclonal T cells that acquire phenotypic and cytotoxic properties of natural killer (NK) cells through the cultivation process, becoming so-called T-NK cells. CIK cells can be genetically modified to express CARs. They are minimally alloreactive and can therefore be acquired from haploidentical first-degree relatives. Here, we explored the potential of ERBB2-CAR-modified random-donor CIK cells as a treatment for RMS in xenotolerant mice bearing disseminated high-risk RMS tumors. In otherwise untreated mice, RMS tumors engrafted 13-35 days after intravenous tumor cell injection, as shown by
Identifiants
pubmed: 33193388
doi: 10.3389/fimmu.2020.581468
pmc: PMC7641627
doi:
Substances chimiques
Receptors, Antigen, T-Cell
0
Receptors, Chimeric Antigen
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
581468Informations de copyright
Copyright © 2020 Merker, Wagner, Kreyenberg, Heim, Moser, Wels, Bonig, Ivics, Ullrich, Klingebiel, Bader and Rettinger.
Références
Leukemia. 1999 Aug;13(8):1298-9
pubmed: 10450765
Oncotarget. 2019 Oct 22;10(58):6138-6151
pubmed: 31692914
Int J Mol Sci. 2018 Jan 25;19(2):
pubmed: 29370095
Cancers (Basel). 2019 Jun 03;11(6):
pubmed: 31163679
J Leukoc Biol. 2020 Jul;108(1):363-376
pubmed: 32272502
J Clin Oncol. 2016 Jan 10;34(2):117-22
pubmed: 26503200
Bone Marrow Transplant. 2018 Jul;53(7):891-894
pubmed: 29367709
Mod Pathol. 2006 Sep;19(9):1213-20
pubmed: 16729016
Front Immunol. 2019 May 31;10:1218
pubmed: 31214182
Cancers (Basel). 2019 Aug 21;11(9):
pubmed: 31438563
Immunity. 2018 Mar 20;48(3):399-416
pubmed: 29562192
Expert Opin Biol Ther. 2014 Jul;14(7):905-16
pubmed: 24673175
J Immunol Res. 2016;2016:4684268
pubmed: 27294158
Front Immunol. 2019 Feb 05;10:128
pubmed: 30804938
Blood. 1995 Apr 1;85(7):1954-63
pubmed: 7703498
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Cancer Immunol Res. 2018 Sep;6(9):1100-1109
pubmed: 30030295
Cell Death Dis. 2018 Feb 15;9(3):282
pubmed: 29449531
Blood. 2003 Jan 15;101(2):640-8
pubmed: 12393519
Oncotarget. 2017 Aug 2;8(39):66137-66153
pubmed: 29029499
N Engl J Med. 2018 Jul 5;379(1):64-73
pubmed: 29972754
Blood. 2011 Sep 22;118(12):3301-10
pubmed: 21821703
Int J Cancer. 2016 Oct 15;139(8):1799-809
pubmed: 27253354
Clin Cancer Res. 2013 Aug 1;19(15):4079-91
pubmed: 23785047
Leukemia. 1999 Jan;13(1):110-8
pubmed: 10049045
Pharmacol Ther. 2016 Oct;166:30-9
pubmed: 27373504
Med Pediatr Oncol. 2000 Aug;35(2):96-103
pubmed: 10918230
Mol Ther Oncolytics. 2020 Apr 14;17:278-292
pubmed: 32368616
J Immunol. 1994 Aug 15;153(4):1687-96
pubmed: 7519209
J Exp Med. 1991 Jul 1;174(1):139-49
pubmed: 1711560
J Neurooncol. 2019 Dec;145(3):429-439
pubmed: 31686330
Cytogenet Cell Genet. 1987;45(3-4):148-55
pubmed: 3691179
Cancer Discov. 2014 Feb;4(2):216-31
pubmed: 24436047
J Cancer Res Clin Oncol. 2015 May;141(5):839-49
pubmed: 25381063
Cytotherapy. 2012 Jan;14(1):91-103
pubmed: 21973023
Mol Ther. 2015 Feb;23(2):330-8
pubmed: 25373520
Immunol Cell Biol. 2017 Apr;95(4):356-363
pubmed: 28003642
Blood. 2013 Sep 19;122(12):2030-8
pubmed: 23884859
Nat Commun. 2020 Jul 15;11(1):3549
pubmed: 32669548
Exp Hematol. 1993 Dec;21(13):1673-9
pubmed: 7694868
Nat Rev Drug Discov. 2020 Jan;19(1):39-56
pubmed: 31601994
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Front Oncol. 2012 Apr 09;2:32
pubmed: 22655268
J Cancer Res Clin Oncol. 2011 Feb;137(2):305-10
pubmed: 20407789
J Clin Oncol. 2015 May 20;33(15):1688-96
pubmed: 25800760
Hum Gene Ther. 2002 May 1;13(7):803-13
pubmed: 11975847
N Engl J Med. 2018 Feb 1;378(5):449-459
pubmed: 29385376
J Hematol Oncol. 2019 Jul 16;12(1):78
pubmed: 31311607
Cancer Immunol Immunother. 2012 Sep;61(9):1451-61
pubmed: 22310931
Front Immunol. 2020 Apr 22;11:702
pubmed: 32391013
Mol Cancer. 2019 Jan 15;18(1):10
pubmed: 30646912
Clin Cancer Res. 1998 Jan;4(1):145-52
pubmed: 9516963